To provide optimal patient care, community-based medical oncologists must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with HER2-altered NSCLC and the clinical utility of agents that could significantly impact patient outcomes. As novel ADCs emerge, clinical decision-making and treatment sequencing will become increasingly complex, underscoring a need for continuing education. To successfully integrate novel therapies into practice and drive sustainable patient outcomes, clinicians caring for patients with HER2-altered NSCLC need to stay abreast of the latest clinical trial data and evidence-based guidelines, along with optimal AE management strategies.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedFeb 11, 2026
-
Last day to claim creditFeb 12, 2027 4 months left
-
touchIME, USF Health Advancing the management of HER2-altered NSCLC – Interpreting the latest clinical trial data
-
PRIME Education, Inc. (PRIME®) From Fragmentation to Precision: Translating QI Insights Into Optimized HER2-Altered NSCLC Care
-
Clinical Care Options, LLC (dba Decera Clinical Education) Implementing Systemic Therapy in H3 K27 Altered DMG: Practical Strategies to Optimize Postradiation Care
-
Plexus Communications +1 Targeting HER2 in Advanced NSCLC: Translating Evidence Into Equitable, Personalized Care for Veterans
-
Plexus Communications +1 Advancing EGFR-Mutated NSCLC Management Across Practice Settings: Evidence-Based Approaches to Testing, Treatment Selection, and Sequencing
-
Plexus Communications +1 Targeting EGFR Alterations: Precision Approaches to Frontline Treatment of Late-Stage Non-Small Cell Lung Cancer (NSCLC)
